about
X-linked dominant scapuloperoneal myopathy is due to a mutation in the gene encoding four-and-a-half-LIM protein 1The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluidsThe genetics of multiple sclerosis: review of current and emerging candidatesExtracellular Vesicles in Multiple Sclerosis: What are They Telling Us?Differential micro RNA expression in PBMC from multiple sclerosis patients.Fine mapping and functional analysis of the multiple sclerosis risk gene CD6Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progressionIdentification of ncRNAs as potential therapeutic targets in multiple sclerosis through differential ncRNA - mRNA network analysis.Development and validation of a LC-MS assay for the quantification of ikh12 a novel anti-tumor candidate in rat plasma and tissues and its application in a pharmacokinetic study.Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosisSncRNA (microRNA &snoRNA) opposite expression pattern found in multiple sclerosis relapse and remission is sex dependent.Longitudinal clinical follow-up of a large family with the R357P Twinkle mutation.Neurogenetic disorders in the Basque population.Methods for extracellular vesicles isolation in a hospital setting.Models for Studying Myelination, Demyelination and Remyelination.Mutations in progranulin gene: clinical, pathological, and ribonucleic acid expression findings.Cancer risk in DM1 is sex-related and linked to miRNA-200/141 downregulation.Ferritin-mediated siRNA delivery and gene silencing in human tumor and primary cells.A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis.Inflammaging and Frailty Status Do Not Result in an Increased Extracellular Vesicle Concentration in Circulation.Editorial: Novel Clinical Applications of Extracellular Vesicles.Progressive changes in non-coding RNA profile in leucocytes with age.The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis.Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain).Neural-competent cells of adult human dermis belong to the Schwann lineage.Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA.ERK2 protein regulates the proliferation of human mesenchymal stem cells without affecting their mobilization and differentiation potential.Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain.Replication of top markers of a genome-wide association study in multiple sclerosis in Spain.[Cognitive performance and quality of life in multiple sclerosis in Gipuzkoa].Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection.Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.Increased transcriptional activity of milk-related genes following the active phase of experimental autoimmune encephalomyelitis and multiple sclerosis.Minimizing creatine kinase variability in rats for neuromuscular research purposes.Cognitive/personality pattern and triplet expansion size in adult myotonic dystrophy type 1 (DM1): CTG repeats, cognition and personality in DM1.Cognitive function in facioscapulohumeral dystrophy correlates with the molecular defect.LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene.Yerba mate (Ilex paraguariensis) inhibits lymphocyte activation in vitro.Age gene expression and coexpression progressive signatures in peripheral blood leukocytes.Circular RNA profiling reveals that circular RNAs from ANXA2 can be used as new biomarkers for multiple sclerosis.
P50
Q24643534-E803829D-0C0B-41B7-95F5-B6117FD9A807Q26825022-C49B2583-FC52-4BB8-83BB-E0E9295EAA89Q26825782-6D646456-AAC8-4E7F-BFAA-210288D9AA6FQ27022494-FAA4B91D-AF63-4369-A8EF-5FBA33155B7FQ33484195-DED4178D-918F-4E8B-A795-294DB90ADE45Q34701324-A7345DF3-7752-435D-A5DF-8E5644EBD42EQ35109078-FF3E50F8-7CF4-4027-821C-B28235B8DA39Q35342948-35ED28AF-B15A-4978-8B25-D9CD4FB8FEFEQ35548131-0C6B3B4A-055E-44F1-A47F-6E488A964275Q36512447-506E35C2-835D-480F-9477-F96E5C3C3424Q36527783-975A705C-CF6A-4631-B75A-2653CDE4A81EQ37679842-BB10FC11-6E73-46A3-BAAE-00FD23D95F4EQ38273952-F9292D36-EF19-42D8-95FB-226E8CC31213Q38391453-3D7E14B0-0A57-43EB-BD02-7C28EA0C99B4Q39325813-9A1F672B-19FF-4764-B323-B76775B7D02CQ40161927-A7CF897B-5474-40E1-A0BB-6E7CA1BF7AC7Q40608595-721BCBEB-AB62-489E-9FC0-F888FCA58B91Q40671749-743DD692-FC71-411E-B26A-DE6A565D5A19Q40761060-DCDA4ABE-C2B6-4CD2-B7A4-0533DA3EA9ECQ41891238-7B9CD008-0128-415B-841B-DBA6A06B925AQ41959310-B004EEC2-AB57-41EA-9144-3DA7B60C6AC4Q42279349-AE088717-6A15-45E6-916F-6D81549D1A5AQ42662127-F8E77462-428B-4CDE-B1AF-6BA817768F35Q42933007-DDE61C8B-1E94-429C-9B39-82F849C8C48EQ43010472-AAF50E9B-D471-4BDC-9E35-FCBA489963A2Q44187783-6AF56E11-D890-48BC-A355-5DDDD3110BB1Q44542344-C33F4F1D-981F-4EFA-A7EC-EA4F5AFFD677Q44608425-96602C83-5F27-43E9-8937-84EC4C22FD8CQ44822764-2008B37F-FD38-4478-B482-7E93D0A714CEQ44961773-49A19024-F0A2-4C1C-9F35-E62AF70B1AC4Q45372857-3D800DEF-7F1F-4BCE-B656-0308CEBE6801Q46490039-0C277A65-4A39-4122-9BAC-A674CB0F2982Q46636440-20AEAA0A-DB04-4FA7-BFA0-89F29509AF43Q46695092-3CEFA224-6834-4937-BF16-A42D4B6DAC07Q47176340-8E9594A6-96F8-4A30-B3A6-78D34FB632C4Q48904473-E4FD39C9-0060-43E9-A936-8980F0BA8DFBQ49085024-5D0084B0-26F1-48D5-B2D1-B018837CCC49Q50227603-1801CA9F-5421-405F-A7D9-2CFC96D41965Q50437252-3603615B-C6FF-4013-BFDE-30BD1E993AE9Q50922749-8D908C20-DA26-4D47-9E5C-C49BDE716EBE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Otaegui
@ast
David Otaegui
@en
David Otaegui
@es
David Otaegui
@nl
David Otaegui
@sl
type
label
David Otaegui
@ast
David Otaegui
@en
David Otaegui
@es
David Otaegui
@nl
David Otaegui
@sl
prefLabel
David Otaegui
@ast
David Otaegui
@en
David Otaegui
@es
David Otaegui
@nl
David Otaegui
@sl
P1053
H-4390-2013
P106
P1153
8367001900
P21
P2798
P31
P3829
P496
0000-0002-6625-5976